#OPC1 Patient Spotlight – In 2016, Jake Javier was paralyzed from the neck down. In late 2022, he is set to graduate with his master’s degree from Duke University.
Hear his story: https://t.co/JFIbVtrG1I
@CIRMnews $LCTX #SCI#Inspiration#StoriesOfHope#ReplaceAndRestore
The #BioFL2022 Company of the Year award was presented to @CatalystForRare, a commercial-stage biotechnology company dedicated to making a meaningful difference in the lives of patients suffering from rare diseases. Congrats!
Join our growing team of professionals who are dedicated to advancing science with the goal of creating a better future. Learn more about your next career move here: https://t.co/LEtgxHxMcd
#Spotlight - Nicole Schreiber, Sr. Director of Clinical Strategy has been an integral member of our team! Nicole’s extensive experience with driving #clinicaltrials and forming strategic partnerships to advance drug development has been invaluable for driving our success.
Our #CEO, Pete O’Heeron, spoke with @HBJ_Chris of the @HouBizJournal to discuss the #Houston area and our #innovative#fibroblast technology.
Read the full article here: https://t.co/KpaHlqxGBY
#Fibroblasts are the most common cell in the body, comprising the main cell type of connective tissue. Fibroblasts have been shown to be more effective and potent than #stemcells in the #regeneration of tissue and reduction in #inflammation.
Learn more: https://t.co/bDDpnde9Lf
New ideas are transforming the #healthcare industry. In this #ClarivatePodcast, we speak with Talking Heads' Jerry Harrison, today a rockstar healthcare entrepreneur, about how innovation is bringing startling ideas to life. Episode drops Aug 23: https://t.co/FK0GO4WttK.
#I2I
Some #radiotherapies targeting #PSMA can cause salivary gland and kidney toxicities. We are using a “Radioantibody”, a #mAb linked to a #radioisotope for precise #tumor-targeting to reduce off-target toxicities and increase the safety profile of our drug.
>https://t.co/D7gF2EYD9L
Convergent’s mission is to utilize antibodies, which have greater specificity and affinity than small ligands, and repurpose them into #radioantibodies to create effective #radiotherapeutics for #cancer. Learn more: https://t.co/D7gF2Fgeyl
.@NespressoUSA disappointed that your Boston #prudential store do not have recycling bags with shipping labels for their customers. Do you expect folks to find a store to drop all used pods? Plus, your store professionals were #unhelpful#rude
#ADDF cofounder @a_hfillit shares a fresh perspective on #Alzheimer's research with @statnews, which now looks beyond #Aduhelm to a broader drug pipeline guided by the biology of aging that targets a combination of age-related changes, creating renewed optimism in the field.
Meet us at 2022 American Society of Clinical Oncology (#ASCO22) Annual Meeting to learn about our full-service capabilities and visit Self Care Catalysts, an #AliraHealth company, booth #2045 to learn about #HealthStorylines, our digital operating system. https://t.co/7mVpIAQ0VH